CADL logo

CADL
Candel Therapeutics Inc

9,043
Mkt Cap
$366.23M
Volume
910,354.00
52W High
$7.25
52W Low
$4.25
PE Ratio
-7.13
CADL Fundamentals
Price
$5.00
Prev Close
$4.98
Open
$4.85
50D MA
$5.32
Beta
1.35
Avg. Volume
1.28M
EPS (Annual)
-$0.721
P/B
5.30
Rev/Employee
$0.00
$228.52
Loading...
Loading...
News
all
press releases
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the company, MarketBeat...
MarketBeat·18d ago
News Placeholder
More News
News Placeholder
FY2030 Earnings Forecast for CADL Issued By HC Wainwright
Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Candel Therapeutics in a research note issued to...
MarketBeat·20d ago
News Placeholder
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7%
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat·21d ago
News Placeholder
Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL
Portolan Capital Management LLC trimmed its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 14.7% during the third quarter, according to the company in its most recent Form 13F...
MarketBeat·22d ago
News Placeholder
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00
Citigroup cut their price objective on shares of Candel Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday...
MarketBeat·22d ago
News Placeholder
Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group
Canaccord Genuity Group reissued a "buy" rating and set a $25.00 price objective on shares of Candel Therapeutics in a research report on Friday...
MarketBeat·22d ago
News Placeholder
Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS
Candel Therapeutics (NASDAQ:CADL - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·23d ago
News Placeholder
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research
Zacks Research upgraded Candel Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday...
MarketBeat·24d ago
News Placeholder
Candel Therapeutics (CADL) Projected to Post Earnings on Thursday
Candel Therapeutics (NASDAQ:CADL) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...
MarketBeat·1mo ago
News Placeholder
Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) Director Paul Manning bought 550,458 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was bought at an...
MarketBeat·1mo ago
<
1
2
...
>

Latest CADL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.